case study 1 mrs dt
Download
Skip this Video
Download Presentation
Case Study #1 Mrs. DT

Loading in 2 Seconds...

play fullscreen
1 / 34

Case Study 1 Mrs. DT - PowerPoint PPT Presentation


  • 148 Views
  • Uploaded on

2010 Guidelines. Case Study #1 Mrs. DT. Case Presentation. Age 59: nine years post-menopause with treated osteoporosis Has always enjoyed excellent health with no past medical or surgical history Comes in for her periodic health exam — concerned about calcium and cardiovascular risk.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Case Study 1 Mrs. DT' - ulani


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
case presentation
Case Presentation
  • Age 59: nine years post-menopause with treated osteoporosis
  • Has always enjoyed excellent health with no past medical or surgical history
  • Comes in for her periodic health exam—concerned about calcium and cardiovascular risk
physical examination
Physical Examination
  • Height = 154 cm (60.5 in.)
  • Weight = 55.5 kg (122 lbs.)
  • No significant changes in height, weight, posture, or gait from previous visits
    • Changes in height and weight can be signs of vertebral fractures
medications
Medications
  • Risedronate 35 mg weekly for past six years
  • Calcium 600 mg + vitamin D 400 IU (single-tablet supplement)
current risk factor assessment
Current Risk Factor Assessment
  • Non-smoker, no regular alcohol consumption
  • No previous history of fracture
  • No parental history of hip fracture
  • No history of systemic glucocorticoid use
  • No comorbidities
  • Diet rich in calcium (1200 mg daily from foods)
  • High caffeine intake
question
Question
  • Were the diagnosis and treatment initiation in line with today\'s guideline recommendations?
reflections on the decision making process
Reflections on theDecision-making Process
  • Previous diagnosis and treatment decisions were largely based on bone density T-scores
  • 2010 osteoporosis guidelines advocate making decisions based on an assessment of overall 10-year fracture risk
  • Tools endorsed: CAROC and FRAX
  • Current recommendations for:
    • Calcium: 1200 mg from diet and supplement combined
    • Vitamin D: 800 – 2000 IU daily for age over 50
mrs dt reflection on diagnosis
Mrs. DT: Reflection on Diagnosis
  • Six years ago, the diagnosis and therapy were appropriate, given the low BMD at the femoral neck (-2.4) and two minor risk factors (weight < 57kg, high caffeine intake)
  • With today\'s tools (e.g., CAROC, FRAX), however, Mrs. DT would have been low risk
    • Treatment would not have been recommended under the current system
question12
Question
  • Would you consider using a risk-assessment tool to check Mrs. DT\'s current level of risk on treatment?
absolute fracture risk tools
Absolute Fracture Risk Tools
  • Calculate risk for treatment-naïve patients only
  • Cannot be used to monitor response to therapy
    • Using CAROC or FRAX in a patient on therapy only reflects the theoretical risk of a hypothetical patient who is treatment naïve and does not reflect the risk reduction associated with therapy
    • One could use these tools to assess what the risk might be for a woman like Mrs. DT who had never been treated
question15
Question
  • What would you do in this case?
  • Would you continue or discontinue treatment with risedronate?
    • Discuss the rationale for your decision
mrs dt conclusions
Mrs. DT: Conclusions
  • Diagnosis and treatment decisions should now be based on 10-year assessment of risk using a validated tool
    • Patients at low risk (10-year risk < 10%) should not be receiving treatment
  • Her current risk level is not known:
    • 10-year absolute risk tools were developed to assess patients who are treatment naive
  • Mrs. DT currently gets adequate calcium from her diet (~1200 mg daily)
    • Calcium supplementation should be stopped
    • Vitamin D supplementation should continue
back up material

Back-up Material

Additional slides that can be accessed from hyperlinks on case slides

Case 1 – Mrs. DT

potential risks of calcium supplementation
Potential Risks of Calcium Supplementation
  • High-dose calcium supplementation has been associated with
    • Renalcalculi in older women
    • Cardiovascular events in older women
    • Prostate cancer in older men

1. Bolland MJ, et al. J Clin Endocrinol Metab 2010; 95(3):1174-1181.

2. Bolland MJ, et al. BMJ 2008; 336(7638):262-266.

3. Reid IR, et al. Osteoporos Int 2008; 19(8):1119-1123.

Return to case

importance of weight
Importance of Weight
  • In men > 50 years and in postmenopausal women, the following are associated with low BMD and fractures
    • Low body weight (< 60 kg)
    • Major weight loss (> 10% of weight at age 25)

1. Papaioannou A, et al. Osteoporos Int 2009; 20(5):703-715.

2. Waugh EJ, et al. Osteoporos Int 2009; 20:1-21.

3. Cummings SR,et al. N Engl J Med 1995; 332(12):767-773.

4. Papaioannou A, et al. Osteoporos Int 2005; 16(5):568-578.

5. Kanis J, et al. Osteoporos Int 1999; 9:45-54.

6. Morin S, et al. Osteoporos Int 2009; 20(3):363-70.

Return to case

importance of height loss
Importance of Height Loss
  • Increased risk of vertebral fracture:
    • Historical height loss (> 6 cm)1,2
    • Measured height loss (> 2 cm)3-5
  • Significant height loss should be investigated by a lateral thoracic and lumbar spineX-ray

1. Siminoski K, et al. Osteoporos Int 2006; 17(2):290-296.

2. Briot K, et al. CMAJ 2010; 182(6):558-562.

3. Moayyeri A, et al. J Bone Miner Res 2008; 23:425-432.

4. Siminoski K, et al. Osteoporos Int 2005; 16(4):403-410.

5. Kaptoge S, et al. J Bone Miner Res 2004; 19:1982-1993.

Return to case

first line therapies with evidence for fracture prevention in postmenopausal women
First Line Therapies with Evidence for Fracture Prevention in Postmenopausal Women*

Return to case

* For postmenopausal women,  indicates first line therapies and Grade A recommendation. For men requiring treatment,alendronate, risedronate, and zoledronic acid can be used as first line therapies for prevention of fractures [Grade D].

+ In clinical trials, non-vertebral fractures are a composite endpoint including hip, femur, pelvis, tibia, humerus, radius, and clavicle.

** Hormone therapy (estrogen) can be used as first line therapy in women with menopausal symptoms.

10 year risk assessment caroc
10-year Risk Assessment: CAROC
  • Semiquantitative method for estimating 10-year absolute risk of a major osteoporotic fracture* in postmenopausal women and men over age 50
    • Stratified into three zones (Low: < 10%, moderate, high: > 20%)
  • Basal risk category is obtained from age, sex, and T-score at the femoral neck
  • Other fractures attributable to osteoporosis are not reflected; total osteoporotic fracture burden is underestimated
  • * Combined risk for fractures of the proximal femur, vertebra [clinical], forearm, and proximal humerus
  • Siminoski K, et al. Can Assoc Radiol J 2005; 56(3):178-188.
10 year risk assessment for women caroc basal risk
10-year Risk Assessment for Women (CAROC Basal Risk)

Papaioannou A, et al. CMAJ 2010 Oct 12. [Epub ahead of print].

10 year risk assessment for women caroc basal risk24
10-year Risk Assessment for Women (CAROC Basal Risk)

Papaioannou A, et al. CMAJ 2010 Oct 12. [Epub ahead of print].

10 year risk assessment for men caroc basal risk
10-year Risk Assessment for Men (CAROC Basal Risk)

Papaioannou A, et al. CMAJ 2010 Oct 12. [Epub ahead of print].

10 year risk assessment for men caroc basal risk26
10-year Risk Assessment for Men (CAROC Basal Risk)

Papaioannou A, et al. CMAJ 2010 Oct 12. [Epub ahead of print].

risk assessment with caroc important additional risk factors
Risk Assessment with CAROC: Important Additional Risk Factors
  • Factors that increase CAROC basal risk by one category (i.e., from low to moderate or moderate to high)
    • Fragility fracture after age 40*1,2
    • Recent prolonged systemic glucocorticoid use**2

* Hip fracture, vertebral fracture, or multiple fracture events should be considered high risk

** >3 months use in the prior year at a prednisone-equivalent dose ≥ 7.5 mg daily

  • 1. Siminoski K, et al. Can Assoc Radiol J 2005; 56(3):178-188.
    • 2. Kanis JA, et al. J Bone Miner Res 2004; 19(6):893-899.

Return to case

risk assessment using frax
Risk Assessment Using FRAX
  • Uses age, sex, BMD, and clinical risk factors to calculate 10-year fracture risk
    • BMD must be femoral neck
    • FRAX also computes 10-year probability of hip fracture alone
  • This system has been validated for use in Canada1
  • There is an online FRAX calculator with detailed instructions at: www.shef.ac.uk/FRAX
  • * composite of hip, vertebra, forearm, and humerus
  • 1. Leslie WD, et al. Osteoporos Int; In press.
frax tool online calculator
FRAX Tool: Online Calculator
  • www.shef.ac.uk/FRAX.
frax clinical risk factors
FRAX Clinical Risk Factors
  • Parental hip fracture
  • Prior fracture
  • Glucocorticoid use
  • Current smoking
  • High alcohol intake
  • Rheumatoid arthritis

Return to case

recommended vitamin d supplementation
Recommended Vitamin D Supplementation

Hanley DA, et al. CMAJ 2010; Jul 26. [epub before print].

vitamin d optimal levels
Vitamin D: Optimal Levels
  • To most consistently improve clinical outcomes such as fracture risk, an optimal serum level of 25-hydroxy vitamin D is probably > 75 nmol/L
    • For most Canadians, supplementation is needed to achieve this level

Hanley DA, et al. CMAJ 2010; 182:E610-E618.

when to measure serum 25 oh d
When to Measure Serum 25-OH-D
  • In situations where deficiency is suspected or where levels would affect response to therapy
    • Individuals with impaired intestinal absorption
    • Patients with osteoporosis requiring pharmacotherapy
  • Should be checked no sooner than three months after commencing standard-dose supplementation in osteoporosis
  • Monitoring of routine supplement use and routine screening of otherwise healthy individuals are not necessary

Return to case

Hanley DA, et al. CMAJ 2010; 182:E610-E618.

recommended calcium intake
Recommended Calcium Intake
  • From diet and supplementscombined: 1200 mg daily
    • Several different types of calciumsupplements are available
  • Evidence shows a benefit ofcalcium on reduction of fracturerisk1
  • Concerns about serious adverse effects with high-dose supplementation2-4

1. Tang BM, et al. Lancet 2007; 370(9588):657-666.

2. Bolland MJ, et al. J Clin Endocrinol Metab 2010; 95(3):1174-1181.

3. Bolland MJ, et al. BMJ 2008; 336(7638):262-266.

4 Reid IR, et al. Osteoporos Int 2008; 19(8):1119-1123.

Return to case

ad